Barclays
PTGX icon

Barclays’s Protagonist Therapeutics PTGX Stock Holding History

Barclays’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Sell
14,405
-173,237
-92% -$15.3M ﹤0.01% 2516
2025
Q4 		$16.4M Buy
187,642
+16,236
+9% +$1.33M ﹤0.01% 1358
2025
Q3 		$11.4M Sell
171,406
-40,706
-19% -$2.31M ﹤0.01% 1565
2025
Q2 		$11.7M Buy
212,112
+100,680
+90% +$4.83M ﹤0.01% 1465
2025
Q1 		$5.39M Sell
111,432
-15,301
-12% -$641K ﹤0.01% 1852
2024
Q4 		$4.89M Sell
126,733
-262
-0.2% -$11.4K ﹤0.01% 2194
2024
Q3 		$5.71M Buy
126,995
+87,755
+224% +$3.55M ﹤0.01% 1976
2024
Q2 		$1.36M Sell
39,240
-22,579
-37% -$661K ﹤0.01% 2404
2024
Q1 		$1.79M Sell
61,819
-87,155
-59% -$2.37M ﹤0.01% 2668
2023
Q4 		$3.42M Sell
148,974
-27,863
-16% -$488K ﹤0.01% 2445
2023
Q3 		$2.95M Sell
176,837
-16,602
-9% -$322K ﹤0.01% 1661
2023
Q2 		$5.34M Sell
193,439
-390,298
-67% -$9.77M ﹤0.01% 1312
2023
Q1 		$13.4M Buy
583,737
+328,850
+129% +$5.52M 0.01% 1042
2022
Q4 		$2.78M Buy
254,887
+38,893
+18% +$328K ﹤0.01% 2019
2022
Q3 		$1.82M Buy
215,994
+192,463
+818% +$1.82M ﹤0.01% 1817
2022
Q2 		$186K Sell
23,531
-20,771
-47% -$251K ﹤0.01% 3471
2022
Q1 		$1.05M Sell
44,302
-76,295
-63% -$2.15M ﹤0.01% 2361
2021
Q4 		$4.12M Buy
120,597
+83,600
+226% +$2.64M ﹤0.01% 1848
2021
Q3 		$656K Buy
36,997
+29,592
+400% +$1.26M ﹤0.01% 3038
2021
Q2 		$333K Sell
7,405
-30,461
-80% -$1.01M ﹤0.01% 3300
2021
Q1 		$981K Buy
37,866
+27,258
+257% +$690K ﹤0.01% 2794
2020
Q4 		$214K Sell
10,608
-3,919
-27% -$84.3K ﹤0.01% 3726
2020
Q3 		$284K Buy
14,527
+1,936
+15% +$36.3K ﹤0.01% 3617
2020
Q2 		$222K Buy
12,591
+6,698
+114% +$84K ﹤0.01% 3989
2020
Q1 		$42K Sell
5,893
-12,561
-68% -$94.1K ﹤0.01% 5332
2019
Q4 		$130K Buy
18,454
+3,956
+27% +$39.3K ﹤0.01% 5323
2019
Q3 		$174K Sell
14,498
-10,477
-42% -$132K ﹤0.01% 5071
2019
Q2 		$302K Sell
24,975
-39,594
-61% -$438K ﹤0.01% 4758
2019
Q1 		$812K Sell
64,569
-4,033
-6% -$35.6K ﹤0.01% 3633
2018
Q4 		$462K Buy
+68,602
New +$544K ﹤0.01% 3882
2018
Q3 		– Sell
-24,527
Closed -$164K – 7338
2018
Q2 		$164K Buy
24,527
+12,650
+107% +$97.1K ﹤0.01% 4883
2018
Q1 		$102K Buy
11,877
+3,661
+45% +$69K ﹤0.01% 5367
2017
Q4 		$171K Buy
8,216
+8,000
+3,704% +$142K ﹤0.01% 4818
2017
Q3 		$4K Sell
216
-248
-53% -$3.43K ﹤0.01% 6500
2017
Q2 		$5K Sell
464
-1,171
-72% -$12.5K ﹤0.01% 6241
2017
Q1 		$20K Buy
1,635
+1,417
+650% +$22.8K ﹤0.01% 5813
2016
Q4 		$5K Buy
+218
New +$4.86K ﹤0.01% 6139

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Barclays's PTGX Position: Q1 2026 in Review

Barclays reduced its Protagonist Therapeutics (PTGX) stake by 92% in Q1 2026, selling an estimated $15.3M and leaving 14,405 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2516.

Barclays first reported a position in PTGX in Q4 2016 and has held it in 37 quarters since. The position peaked at $16.4M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Barclays held 14,405 shares of Protagonist Therapeutics worth $1.52M as of Q1 2026.
  • Barclays sold 173,237 Protagonist Therapeutics shares in Q1 2026, an estimated $15.3M.
  • Protagonist Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2516 holding.
  • Barclays first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 37 quarters since.
  • Barclays's Protagonist Therapeutics position peaked at $16.4M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.